Keymed Biosciences, Inc. (HK:2162) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Keymed Biosciences Inc. has unveiled promising data from its phase I/II clinical study of CM336, a bispecific antibody for treating relapsed or refractory multiple myeloma, at the American Society of Hematology Annual Meeting. The study highlighted CM336’s manageable safety profile and encouraging preliminary efficacy, with significant response rates among patients. This development positions CM336 as a potential novel therapeutic option in the treatment landscape.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.